The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for chronic spontaneous urticaria on April 18, 2025.

Sanofi’s new atopic dermatitis treatment Dupixent has gained EU approval, setting it up for a launch across key European markets. Dupixent (dupilumab) is tipped to be the market leader among a ...

This makes the new indication for Dupixent very important for Sanofi as it searches for a blockbuster to transform its fortunes. The FDA is set to make a decision on Dupixent’s new indication on ...

The FDA has accepted the resubmitted license from Sanofi and Regeneron for a drug treatment for urticaria. Dupixent is now approved in several countries, including the US and EU, for six ...

MAI Capital Management decreased its stake in Sanofi (NASDAQ:SNY – Free Report) by 38.2% during the 3rd quarter, ...

Ariel Investments, an investment management company, released its “Ariel Global Fund” third-quarter 2024 investor letter. A ...

With several high-profile manufacturing outlays already in the books in Europe this year, Sanofi is returning to the bloc in ...

Zacks Research increased their FY2024 EPS estimates for shares of Sanofi in a report issued on Wednesday, November 13th.